종목/VYCO
예정된 실적 발표가 아직 잡히지 않았습니다.
Vycor Medical, Inc. designs, develops, and markets neurological medical devices and therapies in the United States and Europe. The company operates through two segments: Vycor Medical and NovaVision. Its Vycor Medical segment provides devices for neurosurgery comprising ViewSite Brain Access System, a retraction and access system for brain and spine surgeries. The NovaVision segment offers non-invasive computer-based rehabilitation therapies targeted at people who have impaired vision as a result of stroke or other brain injury. It has a license agreement with a German-based partner. It primarily serves hospitals and medical professionals. The company was incorporated in 2005 and is headquartered in Boca Raton, Florida. Vycor Medical, Inc. operates as a subsidiary of Fountainhead Capital Management Ltd.
| 발표일 | 분기 | EPS 예상 | EPS 실제 | Surprise | 매출 실제 | 발표 직후 반응 |
|---|---|---|---|---|---|---|
| 5월 13일 (수) | 2026 Q1 | — | — | — | — | — |
| 3월 31일 (화) | 2025 Q4 | — | — | — | — | 0.0% |
| 0% (0/1) |
| PINC | PGIM Securitized Income ETF | 4B | — | — |
| AMED | Amedisys Inc | 3B | — | — |
애널리스트 의견이 수집되지 않았습니다.